Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme
Authors
Keywords
Glioblastoma, Angiogenesis, Invasion, MET, Alternative neovascularization, Vasculogenic mimicry, Endothelial differentiation
Journal
JOURNAL OF MOLECULAR MEDICINE-JMM
Volume 91, Issue 4, Pages 439-448
Publisher
Springer Nature
Online
2013-03-19
DOI
10.1007/s00109-013-1019-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mechanisms of Glioma-Associated Neovascularization
- (2012) Matthew E. Hardee et al. AMERICAN JOURNAL OF PATHOLOGY
- Laminin alpha 2 enables glioblastoma stem cell growth
- (2012) Justin D. Lathia et al. ANNALS OF NEUROLOGY
- VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex
- (2012) Kan V. Lu et al. CANCER CELL
- Integrin 5 1 Plays a Critical Role in Resistance to Temozolomide by Interfering with the p53 Pathway in High-Grade Glioma
- (2012) H. Janouskova et al. CANCER RESEARCH
- Microarray Analysis Verifies Two Distinct Phenotypes of Glioblastomas Resistant to Antiangiogenic Therapy
- (2012) M. DeLay et al. CLINICAL CANCER RESEARCH
- Bevacizumab for the treatment of high-grade glioma
- (2012) Mustafa Khasraw et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Bevacizumab: overview of the literature
- (2012) Maria Ignez Braghiroli et al. Expert Review of Anticancer Therapy
- Glioblastoma-derived Tumor Cells Induce Vasculogenic Mimicry through Flk-1 Protein Activation
- (2012) Ralph Francescone et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Autocrine VEGF–VEGFR2–Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth
- (2012) Petra Hamerlik et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Transdifferentiation of Glioblastoma Stem-Like Cells into Mural Cells Drives Vasculogenic Mimicry in Glioblastomas
- (2012) S. Scully et al. JOURNAL OF NEUROSCIENCE
- Dedifferentiation of Neurons and Astrocytes by Oncogenes Can Induce Gliomas in Mice
- (2012) D. Friedmann-Morvinski et al. SCIENCE
- Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine Tumors
- (2012) Barbara Sennino et al. Cancer Discovery
- Roles for HIF-1α in neural stem cell function and the regenerative response to stroke
- (2011) Lee Anna Cunningham et al. BEHAVIOURAL BRAIN RESEARCH
- DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy In Vivo
- (2011) J.-L. Li et al. CANCER RESEARCH
- Targeting HIF1α Eliminates Cancer Stem Cells in Hematological Malignancies
- (2011) Yin Wang et al. Cell Stem Cell
- Clinical significance of vasculogenic mimicry in human gliomas
- (2011) Xiao-mei Liu et al. JOURNAL OF NEURO-ONCOLOGY
- Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma
- (2011) David A. Reardon et al. JOURNAL OF NEURO-ONCOLOGY
- A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma
- (2011) Ashwatha Narayana et al. JOURNAL OF NEUROSURGERY
- Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice
- (2011) J. F. de Groot et al. NEURO-ONCOLOGY
- Demonstration of vasculogenic mimicry in astrocytomas and effects of Endostar on U251 cells
- (2011) Zhengcao Liu et al. PATHOLOGY RESEARCH AND PRACTICE
- Transdifferentiation of glioblastoma cells into vascular endothelial cells
- (2011) Y. Soda et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis
- (2010) Tao Xu et al. BMC CANCER
- A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry
- (2010) S. El Hallani et al. BRAIN
- Hypoxia inducible factors in cancer stem cells
- (2010) J M Heddleston et al. BRITISH JOURNAL OF CANCER
- Integrin Alpha 6 Regulates Glioblastoma Stem Cells
- (2010) Justin D. Lathia et al. Cell Stem Cell
- Perivascular Nitric Oxide Activates Notch Signaling and Promotes Stem-like Character in PDGF-Induced Glioma Cells
- (2010) Nikki Charles et al. Cell Stem Cell
- Glioblastoma cells incorporate into tumor vasculature and contribute to vascular radioresistance
- (2010) Candice A. Shaifer et al. INTERNATIONAL JOURNAL OF CANCER
- Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma
- (2010) Tracy T. Batchelor et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme
- (2010) Albert Lai et al. JOURNAL OF CLINICAL ONCOLOGY
- Radiographic patterns of relapse in glioblastoma
- (2010) Marc C. Chamberlain JOURNAL OF NEURO-ONCOLOGY
- Phase II study of sunitinib malate in patients with recurrent high-grade glioma
- (2010) B. Neyns et al. JOURNAL OF NEURO-ONCOLOGY
- Vasculogenic mimicry–potential target for glioblastoma therapy: an in vitro and in vivo study
- (2010) Yinsheng Chen et al. MEDICAL ONCOLOGY
- Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis
- (2010) Suphansa Sawamiphak et al. NATURE
- Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells
- (2010) Lucia Ricci-Vitiani et al. NATURE
- Glioblastoma stem-like cells give rise to tumour endothelium
- (2010) Rong Wang et al. NATURE
- Inhibition of Notch Signaling in Glioblastoma Targets Cancer Stem Cells via an Endothelial Cell Intermediate
- (2010) Koos E. Hovinga et al. STEM CELLS
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
- (2009) Marta Pàez-Ribes et al. CANCER CELL
- Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide
- (2009) Gregor Dresemann et al. JOURNAL OF NEURO-ONCOLOGY
- Development of a novel mouse glioma model using lentiviral vectors
- (2009) Tomotoshi Marumoto et al. NATURE MEDICINE
- Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma
- (2009) F. M. Iwamoto et al. NEUROLOGY
- Expression of Integrin αvβ3in Gliomas Correlates with Tumor Grade and Is not Restricted to Tumor Vasculature
- (2008) Oliver Schnell et al. BRAIN PATHOLOGY
- HIF1α Induces the Recruitment of Bone Marrow-Derived Vascular Modulatory Cells to Regulate Tumor Angiogenesis and Invasion
- (2008) Rose Du et al. CANCER CELL
- Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
- (2008) Teri N. Kreisl et al. JOURNAL OF CLINICAL ONCOLOGY
- An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma
- (2008) Andrew D. Norden et al. JOURNAL OF NEURO-ONCOLOGY
- Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival
- (2008) Ashwatha Narayana et al. JOURNAL OF NEUROSURGERY
- VEGF Trap induces antiglioma effect at different stages of disease
- (2008) Candelaria Gomez-Manzano et al. NEURO-ONCOLOGY
- Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence
- (2008) A. D. Norden et al. NEUROLOGY
- Malignant Gliomas in Adults
- (2008) Patrick Y. Wen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth
- (2008) S. Purhonen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started